AxisBiotix

73 days ago

Skinbiotherapeutics: not doing itself any favours over the Superdrug release

I am not saying that Stuart Ashman has goofed operationally. But in terms of being transparent with investors he really is clueless and I say that in a spirit of Christian compassion.

653 days ago

SkinBioTherapeutics – placing and “retail offer”… and CEO Stuart Ashman talking absolute rubbish, shares still a BUY

SkinBioTherapeutics (SBTX) has announced a placing and “retail offer” at 19p per share to raise, respectively, a minimum of £3 million and up to £0.25 million, with CEO Stuart Ashman stating this is needed “to help with the current commercialisation and development strategy of AxisBiotix in skin health, with our latest venture beginning in acne, as well as providing a stronger financial base to support our strategic partnering discussions around three of our other business pillars. The funding will also support us with working capital and strengthen our balance sheet”. Tom Winnifrith has applied for shares in the offer and we suggest you do too BUT Ashman is talking bollocks and we will be slashing our target price from 150p.

1382 days ago

SkinBioTherapeutics – “Business update”, expect shares to respond positively on further updates soon: BUY!

SkinBioTherapeutics (SBTX) has published a “Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!